Main Menu

The technology pertains to the development of furin-deficient Chinese Hamster Ovary (CHO) cells, specifically the CHO FD11 cell line, which plays a pivotal role in proteolytic maturation of various proteins critical for physiological processes and pathogen virulence. By inhibiting furin, a protease involved in the activation of many important proteins and pathogens, these modified cells provide a unique platform for research into viral infections and potential therapeutic interventions.

The discovery outlined in the Employee Discovery and Invention Report represents a significant advancement in veterinary vaccine technology, specifically targeting the bovine respiratory syncytial virus (bRSV). This innovation involves a "DS2" version of the bRSV F vaccine, which has been engineered to enhance immunogenicity through a prefusion-stabilized form of the F protein, absent of the fusion peptide and reinforced by cavity-filling mutations and inter-protomer disulfides.

The technology involves the adaptation of CHO-DG44 cells to ActiCHO P medium, improving their doubling time and suitability for generating stable cell lines for GMP purposes. These stable cell lines are designed for expressing the RSV F protein stabilized in the prefusion conformation, including the DS-Cav1 mutation, developed by the Vaccine Research Center.

The technology involves a laboratory-derived version of the 2009 pandemic H1N1 virus, produced under Good Manufacturing Practices (GMP) to ensure safety and reproducibility for human studies. It's designed for use in controlled research settings to advance our understanding of influenza pathogenesis and to assess the efficacy of vaccines and drugs.

The PSY2 Bovidae aurbeta/gamma shuttle vector represents a pioneering technology in the field of genetic engineering. This innovative vector system has been designed for use in Bovidae species, potentially offering a novel approach to gene delivery and manipulation. It leverages a dual-functionality mechanism that could enable both autonomous replication and the precise insertion of genetic material.

The development of mRNA vaccines targeting SARS-CoV-2 antigens represents a groundbreaking advancement in vaccine technology. These vaccines, currently in Clinical Phase I, utilize messenger RNA to encode coronavirus antigens, triggering a potent immune response that includes the production of neutralizing antibodies. Unlike traditional vaccines, mRNA vaccines do not use live or inactivated viruses, which enhances safety and allows for rapid development.

The "Adjuvant pro-drug platform for gene delivery and spatiotemporal control over immune activation" is a groundbreaking technology that addresses the limitations of DNA and RNA-based vaccines by providing spatiotemporal control over immune activation. This platform utilizes a cationic polymer with pro-drug Toll-like receptor-7/8 agonists attached, allowing for the complexation of RNA and DNA to form nanoparticles for in vivo administration.

The Thermo-responsive adjuvant scaffolds (TRAS) technology offers a groundbreaking approach to vaccine delivery and immunotherapy. TRAS utilizes carriers consisting of Toll-like receptor agonists (TLRa) attached to linear polymer carriers. These carriers are designed to assemble into particles in vivo, addressing the limitations of current particle-based delivery platforms.

This technology presents innovative methods for manufacturing peptide-based vaccines that effectively induce T cell responses. By linking peptide antigens to adjuvants with hydrophobic blocks, a conjugate vaccine is created that self-assembles into nanoparticles, also known as immunotherapeutic nanoscaffolds (IMNs).

In this groundbreaking approach, a versatile AIDS vaccine technology is tailored to target distinct HIV clades prevalent in different regions, including Clade B for the United States, Clade AG for West Africa, and Clade C for South Africa and India. The vaccine serves a dual purpose, functioning both as a prophylactic and therapeutic solution against HIV/AIDS. Furthermore, it can be employed in synergy with DNA vaccines and the immune-boosting properties of GM-CSF to enhance the immune response.